Empliciti Approval Marks A Trifecta Of New Drugs For Multiple Myeloma
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA clears Bristol/AbbVie’s novel immune-boosting drug elotuzumab in another speedy cancer drug approval.